AbbVie Extends Reach Across Dermatology Markets With Dual Regulatory Wins
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.’s (NYSE: ABBV ) SKYRIZI (risankizumab-rzaa) for children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis. A new 55 mg pre-filled syringe